tbuckley/cabot-search huggingface dataset:
Serum Diagnosis of Syphilis.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Opioids and Deaths
Authors: Josiah D Rich, Traci C Green, Michelle S McKenzie
Journal: New England Journal of Medicine (2011)

To the Editor: We applaud the article by Okie (Nov. 18 issue)1 on the increasing number of overdose deaths, since we have seen far too many patients die prematurely of opioid overdoses. One topic was missing from this article: the usefulness of providing access to naloxone to be administered by laypersons to prevent death from an opioid overdose. Several studies involving illicit-drug users have confirmed that training laypeople to recognize and respond appropriately to an overdose situation is feasible, safe, and effective.2-4 Thousands of lives have been saved with either intramuscular injection or intranasal spray of naloxone.5 If it were the standard of care for physicians who prescribe long-acting opiates to also prescribe accompanying naloxone and provide access to brief training on its use, there would be far fewer overdose deaths. Improving access to prescribed naloxone is one fundamental lifesaving response within a clinician’s reach to directly address the unprecedented “flood of opioids” and “rising tide of deaths.”
ON ANOSOGNOSIA
Authors: HANS OPPENHEIMER, MAX WEISSMAN
Journal: American Journal of Psychiatry (1951)

A 64-year-old male patient became totally blind following a cerebral vascular accident; there was no paralysis. He presented a Korsakow type of psychosis and a persistent anosognosia for his blindness. Despite the presence of optic atrophy it was assumed that the blindness was "essentially" of central origin. It was felt that the anosognosia as such was the result of the diffuse cortical disease and that a "functional" localization was more appropriate than a "topographic" one. It is also our opinion that this hypothesis applies particularly to cases of anosognosia for blindness and not to those who show anosognosia for a defect that involves the postural model of the body.
PNR-21FOUR NEW BRAIN TUMOR ENTITIES EMERGE FROM MOLECULAR CLASSIFICATION OF CNS PNETs
Authors: Dominik Sturm, Brent Orr, Umut Toprak, Volker Hovestadt, David Jones, David Capper, Sjoerd van Rijn, Daisuke Kawauchi, Peter Lichter, Andrey Korshunov, Stefan Pfister, David Ellison, Marcel Kool
Journal: Neuro-Oncology (2016)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial
Authors: Imam Waked, Gamal Shiha, Roula B Qaqish, Gamal Esmat, Ayman Yosry, Mohamed Hassany, Reham Soliman, Mohammad A Mohey, Naglaa Allam, Naglaa Zayed, Tarik Asselah, Coleen Hall, Rebecca Redman, Niloufar Mobashery, Wahid Doss
Journal: The Lancet. Gastroenterology & hepatology (2016)
EPI-07DIAGNOSIS OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN CHILDREN. CAN WE IMPROVE IT?
Authors: Monika Drogosiewicz, Ewa Swieszkowska, Marzena Kwiek, Iwona Filipek, Marta Perek-Polnik, Bozenna Dembowska-Baginska
Journal: Neuro-Oncology (2016)
Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study
Authors: Tabitha Cooney, Adam Lane, Ute Bartels, Eric Bouffet, Stewart Goldman, Sarah E S Leary, Nicholas K Foreman, Roger J Packer, Alberto Broniscer, Jane E Minturn, Chie-Schin Shih, Murali Chintagumpala, Tim Hassall, Nicholas G Gottardo, Hetal Dholaria, Lindsey Hoffman, Brooklyn Chaney, Joshua Baugh, Renee Doughman, James L Leach, Blaise V Jones, Maryam Fouladi, Katherine E Warren, Michelle Monje
Journal: Neuro-Oncology (2017)
Screening Tests for Colorectal Cancer
Authors: Jill Jin
Journal: JAMA (2016)

US Preventive Services Task Force; Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Susan J. Curry, PhD; Karina W. Davidson, PhD, MASc; John W. Epling Jr, MD, MSEd; Francisco A. R. García, MD, MPH; Matthew W. Gillman, MD, SM; Diane M. Harper, MD, MPH, MS; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; C. Seth Landefeld, MD; Carol M. Mangione, MD, MSPH; Douglas K. Owens, MD, MS; William R. Phillips, MD, MPH; Maureen G. Phipps, MD, MPH; Michael P. Pignone, MD, MPH; Albert L. Siu, MD, MPH
Assessing the quality of life of non–Hodgkin lymphoma survivors: A population-based study.
Authors: Rebecca Anne Holland, Brian Richard Bird, Mary Cahill, Conleth G. Murphy, Seamus O'Reilly, Emily O'Connor, Maria Boyce, Rory Crotty
Journal: Journal of Clinical Oncology (2016)

227 Background: Non-Hodgkin Lymphoma survival in Ireland has improved significantly over recent years. However, little survivorship research has been conducted in this country. The aim of this study is to assess the quality of life (QOL) in an Irish population of Non-Hodgkin Lymphoma (NHL) survivors. Methods: High–grade NHL survivors treated in 2 University Hospitals participated in this cross–sectional study by completing the validated Lymphoma specific Functional Assessment of Cancer Therapy (FACT–Lym) questionnaire and Symptom Index–18. Scales were measured using a score from 1 (not at all) to 4 (very much). Raw data was transformed to linear scores, with high scores indicating a higher level of functioning. Linear regression analysis was used to compare scores according to time since diagnosis. Results: Of 87 questionnaires, 47 were completed and returned by NHL survivors (54% response rate). QOL scores improved from time of diagnosis, with the exception of 4–5 years where scores decreased before again improving in the following years. After adjusting for age and sex, statistically significant differences were identified 5+ years after diagnosis in emotional, functional wellbeing and global FACT-Lym scores when compared to 1-2 years after diagnosis. Conclusions: QOL improves post diagnosis with a transient decrease at year 4-5 which may represent anxiety prior to being declared ‘cured’ or being discharged from follow–up. Our small, mostly private patient population reported higher QOL than larger government insured American groups (Smith et. al. Health status and quality of life among Non-Hodgkin lymphoma survivors. Cancer. 2009.). Patients reported on–going symptoms after treatment ended. These findings may help to develop a focused cancer survivorship programme in the future. [Table: see text]
Administrative relationships between community mental health centers and academic psychiatry departments: a 12-year update
Authors: E J Douglas, L R Faulkner, J A Talbott, C B Robinowitz, J S Eaton
Journal: American Journal of Psychiatry (1994)

The authors investigated the administrative relationships in 1990 between medical school departments of psychiatry and community mental health centers (CMHCs).A 20-item questionnaire was sent to the chairpersons of the 110 medical school departments of psychiatry with accredited psychiatric residencies.Sixty-nine percent of the chairpersons responded to the questionnaire. Sixty-eight percent of the responding chairpersons reported that their departments had relationships with CMHCs, and 90% of these relationships involved the education of psychiatric residents. Most responding chairpersons described the quality of their existing CMHC relationships as good to excellent. In the most common type of relationship reported the CMHC was used as a setting for resident education. The vast majority of responding chairpersons stated that quality resident education is possible in a CMHC, and about two-thirds of the responding chairpersons with CMHC relationships involving residency education rated the CMHC rotation as of major importance to their residency programs.CMHCs continue to be an important and valued component of the educational experience for many psychiatric residents, and many departments of psychiatry have recognized the advantages and benefits of CMHCs for residency training. There are now considerable data on how a relationship between a medical school department and a CMHC should be structured to achieve maximum benefit for both the department and the CMHC.
Cardiovascular Effects of Chloroquine with Special Reference to Its Antifibrillatory Action
Authors: MARILYN E. HESS, CARL F. SCHMIDT
Journal: Circulation Research (1959)

Intravenous injections of chloroquine terminated experimental atrial fibrillation in open chest dog preparations. Chloroquine and quinidine possess equal vasodilating properties when injected intra-arterially in the same dosage. Chloroquine and quinidine were equally effective in decreasing resting excitability of isolated cat papillary muscle; conduction velocity was markedly slowed by quinidine, but only slightly decreased by chloroquine.
The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study
Authors: Helena Marti-Soler, Camila Hirotsu, Pedro Marques-Vidal, Peter Vollenweider, Gérard Waeber, Martin Preisig, Mehdi Tafti, Sergio Brasil Tufik, Lia Bittencourt, Sergio Tufik, José Haba-Rubio, Raphael Heinzer
Journal: The Lancet Respiratory Medicine (2016)
Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer
Authors: J. A. Lyons, P. Silverman, S. Remick, H. Chen, R. Leeming, R. Shenk, P. Fu, L. Dumadag, K. Escuro, B. Overmoyer
Journal: Journal of Clinical Oncology (2006)

3049 Background: Preclinical models of combination angiogenesis inhibitor bevacizumab (rhuMAbVEGF) and docetaxel demonstrate synergistic suppression of capillary vessel formation. Based upon these data, we developed a randomized phase II trial in order to evaluate the vascular effects on tumor regression with combination bevacizumab/docetaxel vs. docetaxel in the treatment of locally advanced breast cancer. Methods: 49 patients (pts) were randomized to receive neoadjuvant therapy with bevacizumab (10 mg/kg qowk) and docetaxel (two 8-week cycles of 35 mg/m 2 weekly x 6 with a 2 wk break) (BD=24) or docetaxel (D=25) alone. Eligible pts had locally unresectable breast cancer with (n=6) or without distant metastasis (n=43); 16 patients presented with inflammatory breast cancer. Pts whose disease responded, sequentially underwent definitive surgery (4 weeks after BD or D), radiation, 4 cycles of conventional Adriamycin/cyclophosphamide, and tamoxifen or anastrazole (if ER/PR+). Results: Among the 49 pts: 7 clinical CRs, 32 PRs, 5 NR, and 5 PD. Of the 37 pts who underwent surgery: the median number of pathologically positive lymph nodes (LN) was 1 (BD=6, D=1; p=0.228); range 0–20; 43% were LN negative. Neoadjuvant treatment toxicity for both arms was acceptable with no significant differences between the two arms. Grade 4 toxicity included BD - new papillary thyroid cancer (1), neutropenia (1), hyperuricemia (1) and colon perforation (1); and D: - hyperglycemia (1) and hyperuricemia (1). 21 patients in each arm experienced a grade 3 toxicity. There were no episodes of uncontrolled hypertension, proteinuria, or thrombosis. Delayed wound healing (unable to start radiation w/in 6 weeks of surgery) occurred in 8 pts: BD=5; D=3 (p=0.691). Only 1 pt (D) experienced a change in LVEF by &gt; 15% or below the institution’s lower limit of normal. Conclusions: Neoadjuvant therapy for locally advanced breast cancer using docetaxel with bevacizumab is well tolerated. Further studies are required to determine the added efficacy from bevacizumab. Correlative studies on impact of treatment on angiogenesis will be reported separately. (Sponsored by grants: K23CA 87725–01, M01 RR 00080, UO1 CA 62502, 5P30 CA43703-NCI/AVON, Aventis) No significant financial relationships to disclose.
OP27FEASIBILITY OF USING CIRCULATING DENDRITIC CELLS IN CANCER VACCINE TREATMENTS FOR GLIOBLASTOMA
Authors: Adhikaree Jason, Televantos Constantinos, Hogan Louise, Bilimoria Poonam, Jackson Andrew, Patel Poulam
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma (GBM) progression occurs through immune evasion. Furthermore the immunosuppressive drug, dexamethasone (DEX) ameliorates symptoms with unknown effects on the tumour microenvironment. Here we present novel data on GBM patients' four circulating dendritic cells types (DCs) - myeloid type 1 (MDC1) and type 2 (MDC2), slan- (SLAN) and plasmacytoid (pDC), vital for tumour immune detection and orchestrating the cytotoxic response. Furthermore we isolate MDC1 and assess function on exposure to GBM lysate, DEX and manipulation through the mitogen activated protein kinase, p38. METHOD: (1) 9-parameter whole-blood flow cytometry was used to measure the abundance of circulating DC of both GBM patients and age matched healthy controls. Patients were unselected to represent the clinical breadth of disease status and standard therapies. (2) MDC1 were isolated from peripheral blood by magnetic bead selection of CD1c+ cells (n = 6) and exposed to tumour lysate (U87), DEX and, p38 inhibitor (p38i) prior to stimulation. MDC1 cytokine secretion was measured by ELISA for IL-12 and IL-10. RESULTS: (1) Circulating MDC1, MDC2 and SLAN DCs although showing a trend of reduction, only pDC were significantly supressed in patients (n = 13) compared to age matched healthy controls (n = 14). (2) MDC1s exposed to tumour lysate and/or DEX ablated IL-12 secretion and increased IL-10, representing an immunosuppressive environment. This could be partially reversed by the addition of p38i. CONCLUSION: MDC1 are available in sufficient numbers to consider novel adoptive transfer in cancer vaccines. The addition of p38i polarised cytokine profile to a favourable T cell cytotoxic response, highlighting its potential as a vaccine adjunct.
Abstract 19335: Rescue of Cardiac Function Lost Due to Congenital Defect in Proteasome Heterogeneity
Authors: Felix Trogisch, Franziska Koser, Andreas Jungmann, Oliver Müller, Markus Hecker, Oliver Drews
Journal: Circulation (2015)

The ubiquitin-proteasome system is a major regulator of protein homeostasis in health and disease by targeted proteolysis. Recent findings show that the heterogeneity of proteasome complexes is dynamically altered via elevated incorporation of non-essential proteasome subunits in the pathogenesis of cardiac remodeling. However, the impact of this regulatory event on cardiac remodeling is not known. Therefore, aim of the study was to determine the influence of the non-essential proteasome subunit Lmp2 on cardiac remodeling induced by chronic catecholamine exposure. Wild-type mice subjected to 30mg/kg isoproterenol for 7 days developed cardiac hypertrophy with increased cardiac function (fractional shortening/FS: +18% vs. pre-treatment). In hearts of these mice, Lmp2 showed increased abundance and incorporation in proteasome complexes. Adult mice lacking Lmp2 congenitally seem phenotypically indistinguishable from wild-types, but developed exacerbated cardiac hypertrophy with decreased cardiac function (FS: -27% vs. wt) upon continuous isoproterenol stimulation. Myocardial transfer of the gene encoding Lmp2 via adeno-associated virus in adult mice resulted in the expression of its processed form comparable to wild-type levels with no obvious phenotypic effects under unstimulated conditions. Upon catecholamine challenge, increasing levels of processed Lmp2 were detected in hypertrophied hearts, suggesting induced functional incorporation in proteasome complexes similar to observations previously made in wild-type animals. Re-expression of Lmp2 reduced the extent of cardiac remodeling in mice congenitally lacking this subunit and rescued cardiac function at least in part (FS: +13% vs. treated virus control). In conclusion, the study demonstrates for the first time that induced expression of the non-essential proteasome subunit Lmp2 is a regulatory mechanism of targeted proteolysis, which mitigates cardiac remodeling and contributes to maintaining cardiac function.
Salivary prostaglandin concentrations: possible state indicators for major depression
Authors: S Nishino, R Ueno, K Ohishi, T Sakai, O Hayaishi
Journal: American Journal of Psychiatry (1989)

Salivary prostaglandin concentrations were determined in 42 patients with major depressive disorder, 16 patients with minor depressive disorder, and 39 healthy control subjects. The diagnoses were made according to the Research Diagnostic Criteria. The patients with major depressive disorder had higher salivary prostaglandin concentrations than the control subjects, but the patients with minor depressive disorder did not. Furthermore, the salivary prostaglandin concentrations of the patients with major depressive disorder showed a high correlation with the severity of the depression. These results suggest that high salivary prostaglandin concentrations may be state indicators for major depression.
Implantable tissue-engineered blood vessels from human induced pluripotent stem cells
Authors: Liqiong Gui, Biraja C. Dash, Jiesi Luo, Lingfeng Qin, Liping Zhao, Kota Yamamoto, Takuya Hashimoto, Hongwei Wu, Alan Dardik, George Tellides, Laura E. Niklason, Yibing Qyang
Journal: Biomaterials (2016)
A Nordic Population-Based Cohort Study of Risk of Arterial Thrombotic and Venous Thromboembolic Events in Patients with Primary Chronic Immune Thrombocytopenia (cITP)
Authors: Christian F Christiansen, Karynsa Cetin, Merete Lund Mægbæk, Waleed Ghanima, Shahram Bahmanyar, Scott Stryker, Mette Nørgaard
Journal: Blood (2014)
Androgen Deprivation Therapy and Alzheimer's Disease
Authors: Michael Froehner, Manfred P. Wirth
Journal: Journal of Clinical Oncology (2016)

The study by Nead et al 1 reported a relationship between androgen deprivation therapy and future risk of Alzheimer's disease in men with prostate cancer.In their article, androgen deprivation therapy was clearly used more often in patients with factors that were found to be associated with a higher incidence of Alzheimer's disease. 2 It is conceivable that further unmeasured or hidden confounders were present to put the hormonal treatment population at a disadvantage.For instance, hormonal treatment could have been used less critically in patients with mild symptoms of dementia or in those of lower socioeconomic status.It is hardly possible to control for such confounders in a population that underwent meaningful selection by use of the treatment of interest as in this study. 1In a more homogeneous sample that was possibly less susceptible to selection by Alzheimer's disease-related risk factors, such as brachytherapy for prostate cancer with or without luteinizing hormone-releasing hormone agonist therapy, use of luteinizing hormone-releasing hormone agonist was associated with a decreased risk of death from Alzheimer's disease. 3Unless the results from Nead et al 1 will be reproduced in largely unselected samples or in randomized trials, the association observed between androgen deprivation therapy and risk of Alzheimer's disease should be communicated with caution, particularly to patients with prostate cancer in whom early hormonal treatment may be associated with meaningful clinical benefit. 4,5
CNS metastases: one's too many.
Authors: A Lekos, M J Glantz
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.8.3019 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9256145 CNS metastases: one's too many. A LekosxA LekosSearch for articles by this author , M J GlantzxM J GlantzSearch for articles by this author Show More Memorial Hospital of Rhode Island, Pawtucket, USA. https://doi.org/10.1200/JCO.1997.15.8.3019 PDF "CNS metastases: one's too many.." Journal of Clinical Oncology, 15(8), pp. 3019–3020© 1997 by American Society of Clinical Oncology
Role of New Chemotherapy Agents in Soft Tissue Sarcoma
Authors: Margaret von Mehren
Journal: Journal of the National Comprehensive Cancer Network (2005)

Medical management of soft tissue sarcomas (STS) has been restricted by the limited availability of active drugs. A plethora of new oncologic agents are now available, many of which have specific therapeutic targets. Gemcitabine and docetaxel is a combination of drugs that have limited single-agent activity. Yondelis, a novel chemotherapeutic that binds DNA and functions partially by inhibiting transcription, is being tested alone and in combination with doxorubicin. Inhibitors of mTOR, a serine/threonine kinase that regulates cell cycle activation and cell growth, are also being tested. Growth factor receptor inhibitors are being evaluated in a variety of sarcomas that have been found to express the targets. In addition, a variety of agents are being assessed in gastrointestinal stromal tumors (GIST). Single agents and agents combined with imatinib are being tested in imatinib-refractory and in metastatic GIST. The increased use of targeted agents underscores the need for understanding sarcoma biology.
Health care: for patients or for profits?
Authors: L Eisenberg
Journal: American Journal of Psychiatry (1986)

The author contends that the medical-industrial complex has come to dominate a substantial and growing segment of the health care "market." This complex is characterized by its ability to charge and collect for services, pass through its capital costs, and skim off profitable patients--and, at the same time, to shun its proportionate responsibility for the medically indigent, for the costs of medical education and research, and for meeting community needs. He concludes that physicians have an ethical imperative to join in a broad public coalition to protect equity and quality in medical care.
HG-46RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMAS: CLINICAL, BIOLOGICAL, RADIOLOGICAL AND THERAPEUTIC FACTORS CORRELATING WITH THE SURVIVAL
Authors: Géraldine Giraud, David Castel, Cathy Philippe, Claire Briandet, Fanny Fouyssac, Emilie De Carli, Christelle Dufour, Christian Sainte-Rose, Thomas Blauwblomme, Kevin Beccaria, Michel Zerah, Stephanie Puget, Pascale Varlet, Nathalie Boddaert, Jacques Grill
Journal: Neuro-Oncology (2016)
Influence of Bone-Marrow Injections on Involution and Neoplasia of Mouse Thymus after Systemic Irradiation23
Authors: Henry S. Kaplan, Mary B. Brown, Janice Paull
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article Influence of Bone-Marrow Injections on Involution and Neoplasia of Mouse Thymus after Systemic Irradiation Get access Henry S. Kaplan, Henry S. Kaplan Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary B. Brown, Mary B. Brown Search for other works by this author on: Oxford Academic PubMed Google Scholar Janice Paull Janice Paull Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 2, October 1953, Pages 303–316, https://doi.org/10.1093/jnci/14.2.303 Published: 01 October 1953 Article history Received: 27 May 1953 Published: 01 October 1953